People with rheumatoid arthritis treated with rituximab or JAK-inhibitors had worse outcomes when infected with COVID-19 when compared with those on TNF inhibitors, analysis of a large global registry suggests. The study looking at differences in outcomes from COVID-19 infection in patients who were taking biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) highlights ...
COVID outcomes worse in RA patients on rituximab or JAK-inhibitors, global registry shows
By Emma Wilkinson
3 Jun 2021